Increasing access to rapid diagnostic testing for Mpox

Description of impact

Through a multi-site clinical and laboratory study in Uganda and Democratic Republic of Congo we are evaluating the accuracy of rapid antigen tests to accelerate their approval for use in routine care of mpox patients. Unlike the PCR tests that require laboratory facilities, the antigen tests will be used at point of care in clinics and homes hence increasing access to diagnosis of mpox in hard to reach areas.

Who is affected

Over 200 million people in East and Central Africa are at risk of suffering from mpox disease.

Narrative

Mpox, declared a Public Health Emergency by WHO in August 2024, is spreading rapidly in East and Central Africa. Current PCR tests are hard to access, creating an urgent need for rapid antigen tests. Our project, starting in November 2024, will use 500 rapid antigen kits to benefit 500 patients in Uganda and DRC. We aim to validate these tests for wider use, improving diagnosis and management of Mpox. This research will support timely patient care and inform policy, potentially benefiting thousands more in the region.

Impact status	Open
Impact date	15 Nov 2024 → 30 Oct 2025
Category of impact	Health and Welfare Impact
Impact level	Involvement - mid or active stage